MRK RSI Chart
Last 7 days
-2.8%
Last 30 days
-1.8%
Last 90 days
0.9%
Trailing 12 Months
8.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 61.4B | 0 | 0 | 0 |
2023 | 57.9B | 58.3B | 59.3B | 60.1B |
2022 | 54.0B | 57.2B | 59.0B | 59.3B |
2021 | 41.0B | 43.0B | 45.2B | 48.7B |
2020 | 40.4B | 38.0B | 36.5B | 42.4B |
2019 | 43.1B | 44.4B | 46.0B | 39.1B |
2018 | 40.7B | 41.3B | 41.7B | 42.3B |
2017 | 39.9B | 40.0B | 39.8B | 40.1B |
2016 | 39.4B | 39.4B | 39.9B | 39.8B |
2015 | 41.4B | 40.2B | 39.8B | 39.5B |
2014 | 43.6B | 43.5B | 43.1B | 42.2B |
2013 | 46.2B | 44.9B | 44.5B | 44.0B |
2012 | 48.2B | 48.4B | 47.8B | 47.3B |
2011 | 46.1B | 47.0B | 47.8B | 48.0B |
2010 | 33.5B | 38.9B | 44.0B | 46.0B |
2009 | 24.6B | 25.6B | 27.0B | 27.4B |
2008 | 0 | 24.1B | 24.0B | 23.9B |
2007 | 0 | 0 | 0 | 24.2B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | smart dalton | acquired | 49,072 | 128 | 381 | svp fin. - global controller |
May 02, 2024 | romanelli joseph | sold (taxes) | -143,612 | 128 | -1,115 | president, human health int?l |
May 02, 2024 | smart dalton | sold (taxes) | -16,872 | 128 | -131 | svp fin. - global controller |
May 02, 2024 | romanelli joseph | acquired | 291,346 | 128 | 2,262 | president, human health int?l |
Feb 14, 2024 | davis robert m | sold | -10,661,600 | 125 | -85,021 | chairman, ceo & president |
Feb 14, 2024 | davis robert m | acquired | 6,268,600 | 73.73 | 85,021 | chairman, ceo & president |
Feb 14, 2024 | litchfield caroline | sold | -4,805,520 | 125 | -38,291 | evp & cfo |
Feb 14, 2024 | litchfield caroline | acquired | 2,223,940 | 58.08 | 38,291 | evp & cfo |
Feb 13, 2024 | davis robert m | acquired | 11,127,200 | 74.1811 | 150,000 | chairman, ceo & president |
Feb 13, 2024 | romanelli joseph | sold | -124,888 | 124 | -1,000 | president, human health int?l |
Which funds bought or sold MRK recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 02, 2024 | TOBAM | reduced | -32.34 | -6,079,000 | 27,491,000 | 2.46% |
May 02, 2024 | Poplar Forest Capital LLC | reduced | -2.77 | 4,526,600 | 30,130,400 | 4.05% |
May 02, 2024 | WRIGHT INVESTORS SERVICE INC | added | 2.95 | 1,016,880 | 5,148,950 | 1.30% |
May 02, 2024 | Mendel Money Management | reduced | -1.21 | 176,573 | 1,078,820 | 0.50% |
May 02, 2024 | Mathes Company, Inc. | unchanged | - | 150,000 | 864,000 | 0.32% |
May 02, 2024 | Asset Management One Co., Ltd. | reduced | -2.45 | 25,892,300 | 167,080,000 | 0.64% |
May 02, 2024 | Stack Financial Management, Inc | reduced | -1.33 | 4,733,980 | 29,110,400 | 2.67% |
May 02, 2024 | Ramsay, Stattman, Vela & Price, Inc. | reduced | -2.85 | 678,567 | 4,538,420 | 0.87% |
May 02, 2024 | TOKIO MARINE ASSET MANAGEMENT CO LTD | added | 0.14 | 4,050,090 | 23,156,800 | 1.17% |
May 02, 2024 | Blume Capital Management, Inc. | reduced | -4.17 | 41,837 | 303,485 | 0.07% |
Unveiling Merck & Co Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Merck & Co Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 359.2B | 85.6B | 9.34 | 4.19 | ||||
MRK | 323.0B | 61.4B | 140.05 | 5.26 | ||||
AMGN | 166.9B | 29.5B | 44.36 | 5.65 | ||||
PFE | 157.1B | 46.5B | -113.14 | 3.37 | ||||
GILD | 80.7B | 27.1B | 14.25 | 2.98 | ||||
TEVA | 15.6B | 15.8B | -27.18 | 0.99 | ||||
MID-CAP | ||||||||
PRGO | 4.4B | 4.7B | -349.99 | 0.95 | ||||
ALKS | 4.1B | 1.7B | 9.38 | 2.36 | ||||
BHC | 2.9B | 9.0B | -6.3 | 0.32 | ||||
AMPH | 2.0B | 644.4M | 14.84 | 3.17 | ||||
SMALL-CAP | ||||||||
TLRY | 1.6B | 743.2M | -4.6 | 2.18 | ||||
TXMD | 22.0M | 1.3M | -2.14 | 16.92 | ||||
ACRX | 17.1M | - | -0.93 | 0.22 | ||||
AGRX | 2.5M | 19.6M | -0.17 | 0.13 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Merck & Co Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 7.8% | 15,775 | 14,631 | 15,962 | 15,035 | 14,487 | 13,830 | 14,959 | 14,593 | 15,901 | 13,521 | 13,154 | 11,402 | 10,627 | 10,064 | 10,929 | 9,353 | 12,057 | 4,149 | 12,397 | 11,760 | 10,816 |
S&GA Expenses | -11.4% | 2,483 | 2,804 | 2,519 | 2,702 | 2,479 | 2,687 | 2,520 | 2,512 | 2,323 | 2,830 | 2,336 | 2,281 | 2,187 | 2,437 | 2,060 | 2,085 | 2,555 | 1,729 | 2,589 | 2,712 | 2,425 |
R&D Expenses | -58.5% | 3,992 | 9,627 | 3,307 | 13,321 | 4,276 | 3,775 | 4,399 | 2,798 | 2,576 | 3,068 | 2,445 | 4,321 | 2,412 | 5,771 | 3,349 | 2,085 | 2,209 | 2,400 | 3,204 | 2,189 | 1,931 |
EBITDA Margin | 51.8% | 0.09* | 0.06* | 0.15* | 0.12* | 0.29* | 0.31* | 0.32* | 0.35* | 0.32* | 0.32* | 0.19* | 0.14* | - | - | - | - | - | - | - | - | - |
Income Taxes | 210.1% | 903 | -820 | 870 | 637 | 825 | 496 | 330 | 538 | 554 | 85.00 | 695 | 503 | 238 | 7.00 | 380 | 396 | 619 | 306 | 440 | 615 | 205 |
Earnings Before Taxes | 377.1% | 5,670 | -2,046 | 5,620 | -5,335 | 3,650 | 3,513 | 3,583 | 4,487 | 4,861 | 3,909 | 5,266 | 1,717 | 2,987 | -2,983 | 2,706 | 2,741 | 3,838 | -1,502 | 2,347 | 3,259 | 3,067 |
EBT Margin | 102.6% | 0.06* | 0.03* | 0.13* | 0.09* | 0.26* | 0.28* | 0.29* | 0.32* | 0.29* | 0.28* | 0.15* | 0.10* | - | - | - | - | - | - | - | - | - |
Net Income | 488.4% | 4,762 | -1,226 | 4,745 | -5,975 | 2,821 | 3,017 | 3,248 | 3,944 | 4,310 | 3,758 | 4,567 | 1,545 | 3,179 | -2,094 | 2,941 | 3,002 | 3,219 | 2,357 | 1,901 | 2,670 | 2,915 |
Net Income Margin | 518.5% | 0.04* | 0.01* | 0.08* | 0.05* | 0.23* | 0.24* | 0.26* | 0.29* | 0.26* | 0.27* | 0.16* | 0.13* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 400.0% | 2,229 | -743 | 6,710 | 2,697 | 332 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -0.8% | 105,849 | 106,675 | 106,727 | 104,469 | 107,796 | 109,160 | 107,081 | 107,095 | 106,668 | 105,694 | 93,494 | 90,688 | 90,847 | 91,588 | 89,800 | 90,615 | 84,913 | 84,397 | 83,331 | 83,965 | 82,354 |
Current Assets | -2.2% | 31,445 | 32,168 | 31,954 | 29,977 | 33,402 | 35,722 | 33,561 | 32,116 | 31,184 | 30,266 | 31,058 | 28,665 | 26,909 | 27,764 | 26,577 | 29,343 | 26,174 | 27,483 | 26,142 | 24,298 | 25,351 |
Cash Equivalents | -17.1% | 5,671 | 6,841 | 8,605 | 5,660 | 9,707 | 12,694 | 11,279 | 9,753 | 8,614 | 8,167 | 10,046 | 8,630 | 6,882 | 8,153 | 7,401 | 11,147 | 7,460 | 9,934 | 7,871 | 6,660 | 8,077 |
Inventory | 2.4% | 6,510 | 6,358 | 6,131 | 5,930 | 5,863 | 5,911 | 5,614 | 5,535 | 5,774 | 5,953 | 5,603 | 5,499 | 6,402 | 5,554 | 6,128 | 6,056 | 5,846 | 5,978 | 5,855 | 5,847 | 5,712 |
Net PPE | 0.0% | 23,045 | 23,051 | 22,526 | 22,231 | 21,758 | 21,422 | 20,424 | 20,059 | 19,747 | 19,279 | 18,565 | 18,064 | 18,295 | 17,000 | 16,919 | 15,789 | 15,269 | 14,297 | 14,287 | 13,862 | 13,506 |
Goodwill | -0.1% | 21,181 | 21,197 | 21,183 | 21,195 | 21,209 | 21,204 | 21,160 | 21,213 | 21,258 | 21,264 | 18,862 | 18,873 | 20,212 | 18,882 | 20,248 | 239 | 19,767 | 18,069 | 19,480 | 19,490 | 1,376 |
Current Liabilities | -2.3% | 25,099 | 25,694 | 23,094 | 23,394 | 23,131 | 24,239 | 22,998 | 23,168 | 22,316 | 23,872 | 23,728 | 21,906 | 26,361 | 27,327 | 20,405 | 22,178 | 23,483 | 22,220 | 20,684 | 20,085 | 18,543 |
Long Term Debt | -7.5% | 31,142 | 33,683 | 33,972 | 34,072 | 28,074 | 28,745 | 28,482 | 28,684 | 30,586 | 30,690 | 22,907 | 24,033 | 24,002 | 25,360 | 26,321 | 26,156 | 21,637 | 22,736 | 22,677 | 22,771 | 22,721 |
LT Debt, Non Current | -100.0% | - | 33,683 | 33,972 | 34,072 | 28,074 | 28,745 | 28,482 | 28,684 | 30,586 | 30,690 | 22,907 | 24,033 | 24,002 | 25,360 | 26,321 | 26,156 | 21,637 | 22,736 | 22,677 | 22,771 | 22,721 |
Shareholder's Equity | 7.6% | 40,424 | 37,581 | 41,246 | 38,742 | 46,905 | 45,991 | 44,524 | 43,318 | 40,953 | 38,257 | 35,863 | 33,388 | 27,039 | 25,404 | 29,270 | 27,744 | 26,300 | 26,001 | 26,925 | 27,737 | 27,670 |
Retained Earnings | 5.2% | 56,697 | 53,895 | 57,082 | 54,198 | 62,039 | 61,081 | 59,928 | 58,437 | 56,252 | 53,696 | 51,691 | 48,777 | 48,888 | 47,362 | 51,107 | 49,724 | 48,272 | 46,602 | 45,804 | 45,295 | 44,065 |
Additional Paid-In Capital | 0.2% | 44,598 | 44,509 | 44,358 | 44,219 | 44,467 | 44,379 | 44,243 | 44,115 | 44,275 | 44,238 | 44,149 | 44,039 | 39,613 | 39,588 | 39,489 | 39,373 | 39,697 | 39,660 | 39,561 | 39,484 | 38,768 |
Accumulated Depreciation | 1.9% | 18,620 | 18,266 | 18,446 | 18,432 | 18,256 | 17,985 | 17,921 | 17,798 | 18,498 | 18,192 | 18,155 | 18,236 | 18,732 | 18,162 | 18,572 | 18,182 | 17,706 | 17,686 | 17,281 | 17,049 | 16,623 |
Minority Interest | 11.1% | 60.00 | 54.00 | 54.00 | 49.00 | 71.00 | 67.00 | 66.00 | 75.00 | 70.00 | 73.00 | 69.00 | 94.00 | 94.00 | 87.00 | 84.00 | 102 | 95.00 | 94.00 | 87.00 | 102 | 131 |
Float | - | - | - | - | 292,929 | - | - | - | 230,820 | - | - | - | 196,870 | - | - | - | 195,461 | - | - | - | 215,106 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | 1156.1% | 3,090 | 246 | 7,717 | 3,704 | 1,339 | 4,430 | 5,602 | 4,302 | 4,761 | 5,095 | 4,797 | 1,990 | 1,240 | 3,410 | 1,582 | 1,918 | 707 | 238 | 4,226 | 3,084 | 1,336 |
Share Based Compensation | 5.4% | 176 | 167 | 164 | 169 | 145 | 145 | 139 | 137 | 120 | 119 | 117 | 132 | 111 | 99.00 | 126 | 121 | 108 | 83.00 | 101 | 111 | 93.00 |
Cashflow From Investing | -2696.2% | -1,376 | 53.00 | -334 | -11,443 | -2,359 | -1,748 | -962 | -1,077 | -1,173 | -12,049 | -1,061 | -2,625 | -686 | -4,697 | -2,086 | -782 | -1,628 | -663 | 191 | -2,425 | 368 |
Cashflow From Financing | -25.3% | -2,814 | -2,245 | -4,269 | 3,758 | -2,054 | -1,554 | -2,702 | -1,777 | -3,086 | 5,207 | -2,274 | 2,262 | -2,098 | 1,372 | -3,851 | 1,137 | -1,490 | -2,011 | -3,152 | -2,084 | -1,614 |
Dividend Payments | 5.3% | 1,950 | 1,852 | 1,855 | 1,885 | 1,853 | 1,750 | 1,747 | 1,770 | 1,745 | 1,643 | 1,649 | 1,673 | 1,645 | 1,542 | 1,545 | 1,577 | 1,551 | 1,405 | 1,394 | 1,468 | 1,428 |
Buy Backs | -69.0% | 122 | 393 | 466 | 338 | 149 | - | - | - | - | 18.00 | 583 | 239 | - | - | - | - | 1,281 | 1,050 | 1,405 | 1,235 | 1,090 |
Consolidated Statement of (Loss) Income - USD ($) $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Income Statement [Abstract] | |||
Sales | $ 60,115 | $ 59,283 | $ 48,704 |
Costs, Expenses and Other | |||
Cost of sales | 16,126 | 17,411 | 13,626 |
Selling, general and administrative | 10,504 | 10,042 | 9,634 |
Research and development | 30,531 | 13,548 | 12,245 |
Restructuring costs | 599 | 337 | 661 |
Other (income) expense, net | 466 | 1,501 | (1,341) |
Total costs, expenses and other | 58,226 | 42,839 | 34,825 |
Income from Continuing Operations Before Taxes | 1,889 | 16,444 | 13,879 |
Taxes on Income from Continuing Operations | 1,512 | 1,918 | 1,521 |
Net Income from Continuing Operations | 377 | 14,526 | 12,358 |
Less: Net Income Attributable to Noncontrolling Interests | 12 | 7 | 13 |
Net Income from Continuing Operations Attributable to Merck & Co., Inc. | 365 | 14,519 | 12,345 |
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests | 0 | 0 | 704 |
Net Income Attributable to Merck & Co., Inc. | $ 365 | $ 14,519 | $ 13,049 |
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | |||
Income from Continuing Operations (in dollars per share) | $ 0.14 | $ 5.73 | $ 4.88 |
Income from Discontinued Operations (in dollars per share) | 0 | 0 | 0.28 |
Net Income (in dollars per share) | 0.14 | 5.73 | 5.16 |
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | |||
Income from Continuing Operations (in dollars per share) | 0.14 | 5.71 | 4.86 |
Income from Discontinued Operations (in dollars per share) | 0 | 0 | 0.28 |
Net Income (in dollars per share) | $ 0.14 | $ 5.71 | $ 5.14 |
Consolidated Balance Sheet - USD ($) $ in Millions | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 6,841 | $ 12,694 |
Short-term investments | 252 | 498 |
Accounts receivable (net of allowance for doubtful accounts of $88 in 2023 and $72 in 2022) | 10,349 | 9,450 |
Inventories (excludes inventories of $3,348 in 2023 and $2,938 in 2022 classified in Other assets - see Note 8) | 6,358 | 5,911 |
Other current assets | 8,368 | 7,169 |
Total current assets | 32,168 | 35,722 |
Investments | 252 | 1,015 |
Property, Plant and Equipment (at cost) | ||
Land | 326 | 295 |
Buildings | 14,966 | 13,166 |
Machinery, equipment and office furnishings | 17,763 | 16,760 |
Construction in progress | 8,262 | 9,186 |
Property, plant and equipment (at cost) | 41,317 | 39,407 |
Less: accumulated depreciation | 18,266 | 17,985 |
Property, plant and equipment, net | 23,051 | 21,422 |
Goodwill | 21,197 | 21,204 |
Other Intangibles, Net | 18,011 | 20,269 |
Other Assets | 11,996 | 9,528 |
Total Assets | 106,675 | 109,160 |
Current Liabilities | ||
Loans payable and current portion of long-term debt | 1,372 | 1,946 |
Trade accounts payable | 3,922 | 4,264 |
Accrued and other current liabilities | 15,766 | 14,159 |
Income taxes payable | 2,649 | 1,986 |
Dividends payable | 1,985 | 1,884 |
Total current liabilities | 25,694 | 24,239 |
Long-Term Debt | 33,683 | 28,745 |
Deferred Income Taxes | 871 | 1,795 |
Other Noncurrent Liabilities | 8,792 | 8,323 |
Merck & Co., Inc. Stockholders’ Equity | ||
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2023 and 2022 | 1,788 | 1,788 |
Other paid-in capital | 44,509 | 44,379 |
Retained earnings | 53,895 | 61,081 |
Accumulated other comprehensive loss | (5,161) | (4,768) |
Stockholders' equity before deduction for treasury stock | 95,031 | 102,480 |
Less treasury stock, at cost: 1,045,470,249 shares in 2023 and 1,039,269,638 shares in 2022 | 57,450 | 56,489 |
Total Merck & Co., Inc. stockholders’ equity | 37,581 | 45,991 |
Noncontrolling Interests | 54 | 67 |
Total equity | 37,635 | 46,058 |
Total Liabilities and Equity | $ 106,675 | $ 109,160 |
Mr. Robert M. Davis J.D. | |
merck.com | |
Pharmaceuticals | |
65535 |